CoChat

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression

The DOI matches its Crossref record; 131 of the 134 references it cites were found in a registry or an index.

Abstract

Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are identified as safe, well-tolerated rapid-acting antidepressants in adults with treatment-resistant depression, and also mitigate measures of suicidality. Psilocybin is a naturally occurring psychoactive alkaloid and non-selective agonist at many serotonin receptors, especially at serotonin 5-HT 2A receptors, and is found in the Psilocybe genus of mushrooms. Preliminary studies with psilocybin have shown therapeutic promise across diverse populations including major depressive disorder. The pharmacodynamic mechanisms mediating the antidepressant and psychedelic effects of psilocybin are currently unknown but are thought to involve the modulation of the serotonergic system, primarily through agonism at the 5-HT 2A receptors and downstream changes in gene expression. It is also established that indirect effects on dopaminergic and glutamatergic systems are contributory, as well as effects at other lower affinity targets. Along with the direct effects on neurochemical systems, psilocybin alters neural circuitry and key brain regions previously implicated in depression, including the default mode network and amygdala. The aim of this review is to synthesize the current understanding of the receptor pharmacology and neuronal mechanisms underlying the psychedelic and putative antidepressant properties of psiloc…

Overview

Integrity signals

Registry

Crossref · 10.1007/s40263-021-00877-y

Cites

131 of 131 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 131 references

Cited by

See all 127

Metadata

Authors
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., Lin, K., Ho, R., Rosenblat, J. D., Castle, D., & McIntyre, R. S.
Affiliations
  • University Health Network (CA)
  • Guangzhou Medical University (CN)
  • National University of Singapore (SG)
  • Centre for Addiction and Mental Health (CA)
Corresponding author
McIntyre, Roger S.
Venue
CNS Drugs
Published
2021-11-17
Volume
36
Issue
1
Pages
17-30
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W3213007658
Cited by
127
References
134
Citations by year
2026: 25 · 2025: 30 · 2024: 28 · 2023: 34 · 2022: 10
FWCI
2.39
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
psilocybin, depression, rapid-acting antidepressants, treatment-resistant depression, 5-HT2A receptor, serotonergic system, ketamine, esketamine, default mode network, amygdala, dopaminergic system, glutamatergic system, gene expression, receptor pharmacology
MeSH terms
Antidepressive Agents, Brain, Major Depressive Disorder, Depressive Disorder, Major, Humans, Psilocybin, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. https://app.cochat.ai/papers/10.1007/s40263-021-00877-y
The paper
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., Lin, K., Ho, R., Rosenblat, J. D., Castle, D., & McIntyre, R. S. (2022). Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs. https://doi.org/10.1007/s40263-021-00877-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.